secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2023-01-23T23:59:59+00:00
Accession:  0001193125-23-012607
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics: Bexotegrast 320 mg shows significant FVC increase in IPF Phase 2a trial
--------------------------------------------------------------------------------

- 320 mg group met primary/safety endpoints; no drug-related severe/serious adverse events over 12 weeks.
- Mean FVC increase of +29.5 mL from baseline vs placebo decline of 110.7 mL (+140 mL vs placebo, p<0.05 at all timepoints).
- No bexotegrast-treated patients had FVCpp decline ≥10%; QLF progression slowed vs placebo (0.20% vs 1.46%).
- PRO-C3 and integrin beta-6 biomarkers reduced at 4 and 12 weeks (p<0.01 and p<0.0001 vs placebo).
- Phase 2b trial planned for mid-2023; final 24-week data from 320 mg cohort expected Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/0001193125-23-012607-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312523012607/d418942d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-012607

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer